Target intervention against multiple-risk markers to reduce cardiovascular disease in patients with type 2 diabetes

被引：18

作者：

Gæde, P ^{[1
]}

Pedersen, O ^{[1
]}

机构：

[1] Steno Diabet Ctr, DK-2820 Copenhagen, Denmark

来源：

ANNALS OF MEDICINE | 2004年 / 36卷 / 05期

关键词：

cardiovascular disease; combined modality therapy; complication; nephropathy; neuropathy; retinopathy; risk factor; type; 2; diabetes;

D O I：

10.1080/07853890410033612

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The risk of cardiovascular disease is markedly increased in patients with type 2 diabetes with a prevalence twice as high compared to the background population. With the recognition of multiple concomitant risk factors for both microvascular as well as cardiovascular disease in type 2 diabetic patients, treatment strategies have changed during recent years. This review focuses on the many recent drug trials that have set the course for an effective multifactorial treatment of the disease. Thus, the Steno-2 Study has shown that an intensified multifactorial intervention targeting several risk factors for cardiovascular disease is capable of reducing the risk for a combined endpoint of cardiovascular mortality; non-fatal myocardial infarction, non-fatal stroke, coronary interventions, revascularisation to legs, and amputations by 50%.

引用

页码：355 / 366

页数：12

共 48 条

[1] COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS [J].

ALTMAN, R ;

CARRERAS, L ;

DIAZ, R ;

FIGUEROA, E ;

PAOLASSO, E ;

PARODI, JC ;

CADE, JF ;

DONNAN, G ;

EADIE, MJ ;

GAVAGHAN, TP ;

OSULLIVAN, EF ;

PARKIN, D ;

RENNY, JTG ;

SILAGY, C ;

VINAZZER, H ;

ZEKERT, F ;

ADRIAENSEN, H ;

BERTRANDHARDY, JM ;

BRAN, M ;

DAVID, JL ;

DRICOT, J ;

LAVENNEPARDONGE, E ;

LIMET, R ;

LOWENTHAL, A ;

MORIAU, M ;

SCHAPIRA, S ;

SMETS, P ;

SYMOENS, J ;

VERHAEGHE, R ;

VERSTRAETE, M ;

ATALLAH, A ;

BARNETT, H ;

BATISTA, R ;

BLAKELY, J ;

CAIRNS, JA ;

COTE, R ;

CROUCH, J ;

EVANS, G ;

FINDLAY, JM ;

GENT, M ;

LANGLOIS, Y ;

LECLERC, J ;

NORRIS, J ;

PINEO, GF ;

POWERS, PJ ;

ROBERTS, R ;

SCHWARTZ, L ;

SICURELLA, J ;

TAYLOR, W ;

THEROUX, P .

BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6921) :81-100

[2]

[Anonymous], 1990, METABOLISM, V39, P905, DOI 10.1016/0026-0495(90)90299-R

[3]

[Anonymous], 1995, Diabetes in America

[4]

Boner G, 1996, DIABETOLOGIA, V39, P587

[5] Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].

Brenner, BM ;

Cooper, ME ;

de Zeeuw, D ;

Keane, WF ;

Mitch, WE ;

Parving, HH ;

Remuzzi, G ;

Snapinn, SM ;

Zhang, ZX ;

Shahinfar, S .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869

[6] Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT) [J].

Brown, MJ ;

Palmer, CR ;

Castaigne, A ;

de Leeuw, PW ;

Mancia, G ;

Rosenthal, T ;

Ruilope, LM .

LANCET, 2000, 356 (9227) :366-372

[7]

Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3

[8]

Collins R, 2003, LANCET, V361, P2005

[9] Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension [J].

Curb, JD ;

Pressel, SL ;

Cutler, JA ;

Savage, PJ ;

Applegate, WB ;

Black, H ;

Camel, G ;

Davis, BR ;

Frost, PH ;

Gonzalez, N ;

Guthrie, G ;

Oberman, A ;

Rutan, GH ;

Stamler, J .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (23) :1886-1892

[10] MEDITERRANEAN ALPHA-LINOLENIC ACID-RICH DIET IN SECONDARY PREVENTION OF CORONARY HEART-DISEASE [J].

DELORGERIL, M ;

RENAUD, S ;

MAMELLE, N ;

SALEN, P ;

MARTIN, JL ;

MONJAUD, I ;

GUIDOLLET, J ;

TOUBOUL, P ;

DELAYE, J .

LANCET, 1994, 343 (8911) :1454-1459

← 1 2 3 4 5 →